Provided by Tiger Trade Technology Pte. Ltd.

VolitionRX

0.3392
-0.0454-11.80%
Post-market: 0.46400.1248+36.79%18:27 EDT
Volume:55.81M
Turnover:26.07M
Market Cap:4.63M
PE:-0.09
High:0.4688
Open:0.4500
Low:0.3269
Close:0.3846
52wk High:14.80
52wk Low:0.3269
Shares:13.65M
Float Shares:12.33M
Volume Ratio:75.09
T/O Rate:452.48%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8023
EPS(LYR):-4.3726
ROE:-730.06%
ROA:-142.94%
PB:-0.14
PE(LYR):-0.08

Loading ...

VolitionRx Collaborates with Sysmex to Transfer Nu.Q NETs Assay Onto Sysmex Platform

Reuters
·
Yesterday

Press Release: VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets

Dow Jones
·
Yesterday

VolitionRx Study Validates Nu.Q NETs H3.1 Biomarker as Predictor of 28-Day Sepsis Mortality, RRT Need

Reuters
·
Yesterday

VolitionRx Issues 773,361 Shares to Lind Global in Unregistered Note Conversions

Reuters
·
Aug 25

VolitionRX (VNRX) Receives a Buy from Maxim Group

TIPRANKS
·
Aug 18

VolitionRx Posts Corporate Deck Outlining Licensing-Led Strategy for Nu.Q Diagnostics in Cancer, Sepsis, Veterinary Testing

Reuters
·
Aug 14

VolitionRX Q2 EPS $(0.85) Misses $(0.57) Estimate, Sales $398.657K Miss $482.667K Estimate

Benzinga Earnings
·
Aug 14

VolitionRx Q2 FY26 Operating Loss Narrows 34% to $4.2 Million; Operating Expenses Fall 32% on Year

Reuters
·
Aug 14

VolitionRX Limited Announces Second Quarter 2026 Financial Results and Business Update

THOMSON REUTERS
·
Aug 14

VolitionRx Says Finger-Prick Sepsis Test Tracks Lab Nu.Q NETs Assay in Clinical Study

Reuters
·
Aug 12

VolitionRx Gelar Konferensi Kinerja Kuartal II 2026 Dan Pembaruan Bisnis

Reuters
·
Aug 12

VolitionRx Issues 779,371 Shares to Lind Global to Meet Convertible Note Obligations

Reuters
·
Aug 08

VolitionRx Publishes First Peer-Reviewed Paper on Capture-Seq Liquid Biopsy Technology

Reuters
·
Aug 05

Volitionrx - Advances Nu.Q Nets Platform Towards Commercialization

Reuters
·
Jul 30

VolitionRX - Advances Nu.q Nets Platform Towards Commercialization

THOMSON REUTERS
·
Jul 30

VolitionRx Publishes Nu.Q NETs Platform Update Presentation on Sepsis Biomarker Data

Reuters
·
Jul 30

Volitionrx Held Annual Shareholder Meeting; 4,261,161 Shares Represented by Proxy or in Person

Reuters
·
Jul 22

Volitionrx Posts Corporate Deck Outlining Nu.q Licensing Strategy Across Cancer, Sepsis and Veterinary Testing

Reuters
·
Jul 21

Analysts Have Conflicting Sentiments on These Healthcare Companies: Evolus (EOLS), Alkermes (ALKS) and VolitionRX (VNRX)

TIPRANKS
·
Jul 08

Volitionrx Announces Availability of New Press Release

Reuters
·
Jul 07